key: cord-0975239-8chfcxc3 authors: Lehman, Constance D.; Mendoza, Dexter P.; Succi, Marc D.; Kambadakone, Avinash; Lamb, Leslie R. title: Unilateral Lymphadenopathy Post COVID-19 Vaccination: A Practical Management Plan for Radiologists Across Specialties date: 2021-03-04 journal: J Am Coll Radiol DOI: 10.1016/j.jacr.2021.03.001 sha: 164c6381dde52c5261ffd38f2927aab30a0c601d doc_id: 975239 cord_uid: 8chfcxc3 Reports are rising of patients with unilateral axillary lymphadenopathy, visible on diverse imaging examinations, after recent coronavirus disease 2019 vaccination. With less than 10% of the US population fully vaccinated, we can prepare now for informed care of patients imaged after recent vaccination. The authors recommend documenting vaccination information (date[s] of vaccination[s], injection site [left or right, arm or thigh], type of vaccine) on intake forms and having this information available to the radiologist at the time of examination interpretation. These recommendations are based on three key factors: the timing and location of the vaccine injection, clinical context, and imaging findings. The authors report isolated unilateral axillary lymphadenopathy (i.e., no imaging findings outside of visible lymphadenopathy), which is ipsilateral to recent (prior 6 weeks) vaccination, as benign with no further imaging indicated. Clinical management is recommended, with ultrasound if clinical concern persists 6 weeks after the final vaccination dose. In the clinical setting to stage a recent cancer diagnosis or assess response to therapy, the authors encourage prompt recommended imaging and vaccination (possibly in the thigh or contralateral arm according to the location of the known cancer). Management in this clinical context of a current cancer diagnosis is tailored to the specific case, ideally with consultation between the oncology treatment team and radiologist. The aim of these recommendations is to (1) reduce patient anxiety, provider burden, and costs of unnecessary evaluation of enlarged nodes in the setting of recent vaccination and (2) avoid further delays in vaccinations and recommended imaging for best patient care during the pandemic. The first COVID-19 vaccination dose was administered on December 14, 2020 under emergency use authorization from the FDA, and as of February 26, 2021 over 70 million doses have been administered in the US, and 6.8% of the US population has been fully vaccinated [1] . Reactions to the Moderna and Pfizer-BioNTech vaccinations are common, with over 85% of patients reporting local reactions at the injection site and over 75% reporting systemic reactions. The most common unsolicited adverse event reported is unilateral "axillary swelling or tenderness" by 10.2% of patients after the first Moderna vaccine and 14.2% of patients after the second Moderna injection. Patients receiving the Pfizer-BioNTech vaccination have also reported increased rates of palpable unilateral lymphadenopathy (UAL) compared to those receiving a placebo [2] [3] [4] [5] . The percentages of self-reported symptomatic UAL discussed above likely is a subset of the percentage of patients actually experiencing this effect and no doubt is an even smaller percentage of patients whose imaging post COVID-19 vaccination will reveal UAL. Post-COVID-19 vaccination subclinical UAL was first reported on imaging in January 2021, identified incidentally in two women during screening breast ultrasound and in one woman on short-interval follow-up ultrasound of bilateral breast masses [6] . Three cases were subsequently reported in patients undergoing screening breast MRI [7, 8] and two in patients undergoing chest CT [8] . At this time, several subsequent cases of benign UAL post COVID -19 vaccination have been published [9] [10] [11] [12] [13] . Rare cases of UAL identified on imaging after recent ipsilateral upper extremity vaccination have been documented after other vaccinations, including seasonal influenza, Bacille Calmette-Guerin (BCG), human papillomavirus (HPV), and H1N1 [14] [15] [16] [17] [18] [19] [20] [21] . In these prior settings, vaccineinduced lymphadenopathy resulted in false-positive results on PET and CT exams. Lymphadenopathy was visible on imaging as early as one day post vaccination [14] [15] [16] [17] [18] [19] [20] [21] , and in some cases persisted more than one month after vaccination [10, 18] . As the COVID-19 vaccinations provoke a highly immunogenic clinical response in patients, it is reasonable to predict increased frequency of UAL on imaging after COVID-19 vaccination than that reported after other vaccinations, and it is likely the UAL on imaging may persist beyond one month after the final dose. In this early phase of COVID-19 vaccinations, management plans for UAL in the clinical setting of recent vaccination vary widely across practices and range from assessment as "benign" or "normal" with or without clinical follow-up, to immediate additional imaging, to short-interval follow-up imaging (until resolution is documented), to biopsy [6] [7] [8] [9] [10] [11] [12] [13] [22] [23] [24] . Although most cases reported to date involved patients undergoing breast imaging, we have observed increased incidence of patients with UAL on other imaging exams, particularly in oncologic imaging. To guide management across multiple subspecialties in radiology, we first categorize the UAL as presenting in one of three scenarios: 1) as an isolated finding on imaging, 2) in conjunction with another finding on imaging and 3) in a patient undergoing cancer staging and/or treatment ( Figure 1 ). Exclusions Patients with remote vaccination history, bilateral lymphadenopathy and palpable lymphadenopathy are excluded from this management plan. Patients vaccinated more than six weeks in the past are managed following standard "non-COVID-19 vaccination" protocols across subspecialties, as are patients with bilateral axillary lymphadenopathy. We distinguish clinically suspicious, palpable lymphadenopathy presenting for diagnostic imaging from lymphadenopathy noted on imaging as an incidental finding. In the former case, we advocate clinical management and if clinical concerns persist six weeks after final vaccination dose, then we recommend ultrasound for further evaluation and possible biopsy. The first reports of subclinical UAL post COVID-19 vaccinations were made by breast imagers and identified in women undergoing screening MRI, US and mammography [6] [7] [8] . The Society of Breast Imaging (SBI) responded rapidly with guidelines and educational materials for radiologists, referring providers and patients. Suggestions included collecting vaccination history on intake forms and educating patients that axillary swelling is a normal response to vaccinations. For subclinical UAL on screening, the SBI supports BI-RADS 0 assessment to bring screening patients back for further assessment of the ipsilateral breast and documentation of medical and vaccination history. BI-RADS 3 is then recommended with follow-up at 4-12 weeks after the second dose and consideration of BI-RADS 4 (biopsy) if the lymphadenopathy persists at short interval follow-up [24] . Other centers, including ours, recommend consideration of a benign assessment (BI-RADS 2) with clinical follow-up for subclinical isolated UAL in the setting J o u r n a l P r e -p r o o f of a known recent COVID-19 vaccination in the ipsilateral arm, and believe this is consistent with the American College of Radiology (ACR) BI-RADS recommendations for UAL in the setting of a known inflammatory cause [22, 23, 25] . Our specific recommendations have been previously published; briefly, for all patients undergoing breast imaging, we collect vaccination history at the time of the exam, and we tailor our recommendations for three specific clinical settings: screening, diagnostic imaging, and patients in the pre/peri treatment phase of current breast cancer diagnosis [22] (Figure 2 ). Annual lung cancer screening with low-dose chest CT has been shown to reduce lung cancerspecific and all-cause mortalities in select high-risk populations and more than 620,000 studies were performed in 2019 in the US alone [26] [27] [28] . One of the earlier reports of UAL following COVID-19 vaccination was identified on chest CT and appropriately suggested that this may have implications to those undergoing lung cancer screening [8] . Indeterminate extrapulmonary lesions are a common incidental finding on lung cancer screening. Most of these indeterminate lesions are ultimately determined to be benign, but a small subset, including cases of axillary lymphadenopathy, are found to be malignant [29] . No specific guidelines address management of incidental UAL on lung cancer screening. An ACR White Paper addressing the management of incidental mediastinal findings on chest CT, however, recommended further work up (i.e., clinical consultation, PET/CT, or follow-up CT) only in those with mediastinal lymph nodes greater than 15 mm in the short axis without explainable disease [30] . We believe a similar conservative approach can be safely applied to UAL identified during lung cancer screening following recent COVID-19 vaccination. In such cases, UAL can be reported as a potentially significant finding using the "S" modifier of the Lung-RADS reporting system, with clear communication that the UAL is likely reactive and that no further imaging is necessary unless clinical concerns persist six weeks following the final dose of COVID-19 vaccine ( Figure 3 ). Although no national-level data exist, at our institution surveillance imaging exams for patients after cancer treatment comprise the second largest population of cancer-related CT exams, after those with active disease and above screening -including a combination of CT and PET/CT. And, with over 75 million CT scans performed per year in the US, cancer-related surveillance imaging likely contributes many millions of CT scans per year [31] . Consensus guidelines for post-treatment surveillance vary by cancer type, stage at presentation, and may be adjusted by institutional-specific policies. Generally, however, when cross-sectional surveillance is appropriate, including CT surveillance for prostate, melanoma, colon, and lung cancer, intervals typically range from every six months to every two years in patients without evidence of disease, some cases tapering after consecutive years of no evidence of disease [32, 33] . The unprecedented disruption to healthcare caused by the COVID-19 pandemic has significantly impacted the management of oncological patients. This impact is not only related to higher mortality in cancer patients with COVID-19, but also stems from adverse outcomes due to delayed diagnosis, disruption to chemotherapy/surgical therapy and missed/interrupted imaging surveillance. The widespread availability of COVID-19 vaccine has generated hope of return to normalcy in cancer patients with resumption of screening and imaging surveillance. In our oncology imaging practices, we support the following: 1) documentation of COVID-19 vaccine history in the oncological records to ensure its acknowledgement and consideration for timing of imaging and cancer care, 2) education and awareness of vaccine-induced lymphadenopathy for radiologists, multidisciplinary oncology care team and patients and 3) J o u r n a l P r e -p r o o f focused efforts to reassure and counsel patients as they navigate cancer treatment through the pandemic. Concerns or confusion regarding vaccine-induced lymphadenopathy should not delay COVID-19 vaccination, particularly as the mortality related to COVID-19 is higher in cancer patients than the general population [34] . In patients with lymphadenopathy ipsilateral to recent vaccination, management decisions should be individualized based on the type of cancer, staging, lymph node drainage pathway, and overall risk profile. We support the recent recommendations by a panel from Memorial Sloan Kettering, MD Anderson and Dana-Farber cancer centers, which encourage multidisciplinary engagement to tailor patient management based on likelihood the lymphadenopathy is reactive response to vaccination vs. malignancy [10] . Based on the overall risk profile and in consideration of the patient's desires, the full spectrum of management options may be considered: from clinical management without further imaging (for the lowest nodal metastatic risk patients) through immediate additional imaging, short interval follow-up imaging, to biopsy (for the highest nodal metastatic risk patients). For patients who undergo short interval imaging follow-up, time to resolution of UAL on imaging is currently unknown and likely to vary by exam type (e.g., PET/CT vs mammogram) and patient characteristics (e.g., age, comorbidities). Detailed decisions tailored to the individual patient are best supported in a multi-disciplinary setting with proper documentation and after discussion with and input from the patient (Figures 6 and 7) . At this time, three reports have been published to provide guidance in the breast imaging and cancer center settings [10, 22, 24] . All support the following principles: 1) vaccinations should not be delayed 2) vaccination history should be available to the radiologist at time of interpretation of imaging exam 3) in context of known recent vaccination, ipsilateral UAL can be managed clinically without further imaging based on low pre-test probability of malignant lymphadenopathy and 4) patient and referring provider education is essential to avoid confusion and further delays in vaccinations or recommended usual healthcare. While there is general agreement that vaccinations should not be delayed, some recommend performing any recommended imaging prior to vaccination. Based on the local resources, patient populations and access to timely imaging, this approach may inadvertently delay or reduce patient engagement in vaccination programs. Also, perspectives differ regarding postponing imaging until after vaccination. One panel recommended consideration of postponing imaging for screening, routine surveillance and staging for at least six weeks after final vaccination dose [10] and another recommended postponing mammography screening until 4-6 weeks after the final vaccination dose and postponing short interval follow-up for 4-12 weeks after final vaccination dose [24] . After discussion with our primary care colleagues and in careful review of the impact of the pandemic on patient engagement in breast cancer screening, we opted to continue to screen patients without adding further complexities or unintended barriers to screening by delaying or rescheduling exams [22] . Although adjusting scheduling of vaccinations or screening J o u r n a l P r e -p r o o f mammograms for average risk women is not advised, postponing imaging may be reasonable for smaller groups of select patients undergoing surveillance imaging with CT, PET/CT, ultrasound, or MRI. At some centers, screening and/or surveillance examinations may be offered in concert with vaccinations performed on the same day to reduce patient burden and support patient engagement in both domains. The pandemic has exacerbated healthcare disparities. As we consider management of UAL post COVID-19 vaccination and our messaging to the full diversity of patients we serve, care in education and communication is paramount to reduce increasing burdens on our most vulnerable patients. Rescheduling imaging or vaccinations no doubt will be easier for some populations in certain healthcare environments than others. Recommendations to reschedule imaging or vaccinations may discourage racial/ethnic minorities from engaging with health systems at a critical moment, as racial/ethnic minority populations are more likely to suffer from both COVID-19 and delayed cancer diagnoses. In the specific setting of dramatically increased barriers to routine health care and strained healthcare resources due to the pandemic, we continue to focus our efforts to bring patients in for recommended imaging and to use a pragmatic approach for our radiologists and healthcare team to manage UAL in the setting of recent vaccination. in the ipsilateral arm, axillary adenopathy is a benign imaging finding. No further imaging is indicated at this time. If there is clinical concern that persists more than 6 weeks after the patient's final vaccine dose, axillary ultrasound is recommended." for suspicious pulmonary nodules. Given recent COVID-19 vaccination, the case was interpreted as Lung-RADS Category 2. The axillary lymphadenopathy was reported as a "potentially significant finding" using the Lung-RADS "S" modifier. Recommendation was to return to routine annual lung cancer screening. No additional imaging evaluation for the isolated axillary lymphadenopathy was recommended, unless it increases or persists for more than six weeks, at which point an ultrasound may be considered. additional tiny solid nodules up to 3 mm (not shown) were stable compared to priors. There were no new findings in the chest, abdomen or pelvis to suggest active disease. The patient will receive a follow-up chest CT in three months to reassess unrelated incidental pulmonary nodules and the left axillary lymph nodes will be reassessed at that time. Centers for Disease Control and Prevention: COVID data tracker Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Local reactions, systemic reactions, adverse events, and serious adverse events: Pfizer-BioNTech COVID-19 vaccine Local Reactions, systemic reactions, adverse events, and serious adverse events: Moderna COVID-19 vaccine Unilateral axillary lymphadenopathy in the setting of COVID-19 vaccine Management of unilateral axillary lymphadenopathy detected on breast MRI in the era of coronavirus disease (COVID-19) Axillary lymphadenopathy after mRNA COVID-19 vaccination Lymphadenopathy in COVID-19 vaccine recipients: Diagnostic dilemma in oncology patients Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: Radiology scientific expert panel Evolution of lymphadenopathy at PET/MRI after COVID-19 vaccination Adenopathy following COVID-19 vaccination Coronavirus disease (COVID-19) vaccination associated axillary adenopathy: Imaging findings and follow-up recommendations in 23 women Epub ahead of print FDG uptake in axillary lymph nodes after vaccination against pandemic (H1N1) Lymph node activation by PET/CT following vaccination with licensed vaccines for human papillomaviruses Axillary lymph node accumulation on FDG PET/CT after influenza vaccination Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine Duration of 18F-FDG avidity in lymph nodes after pandemic H1N1v and seasonal influenza vaccination False-positive hypermetabolic lesions on post-treatment PET-CT after influenza vaccination False-positive axillary lymph node on FDG-PET/ CT scan resulting from immunization Generalized lymph node activation after influenza vaccination on 18F FDG-PET/CT imaging, an important pitfall in PET interpretation Mitigating the impact of coronavirus disease (COVID-19) vaccinations on patients undergoing breast imaging examinations: A pragmatic approach Membership communications through SBI Connect Open Forum SBI recommendations for the management of axillary lymphadenopathy in patients with recent COVID-19 vaccination: Society of Breast Imaging Patient Care and Delivery Committee Reduced lung-cancer mortality with low-dose computed tomographic screening Reduced lung-cancer mortality with volume CT screening in a randomized trial 2019 Lung cancer screening registry report from the American College of Radiology Detection of extrapulmonary malignancy during lung cancer screening: 5-year analysis at a tertiary hospital Managing incidental findings on thoracic CT: Mediastinal and cardiovascular findings. A white paper of the ACR Incidental Findings Committee Over 75 Million CT Scans are performed each year and growing despite radiation concerns. iData Research Cancer Facts & Figures 2021 NCCN Imaging Appropriate Use Criteria Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies Interim clinical considerations for use of mRNA COVID-19 vaccines | CDC Moderna COVID-19 vaccine standing orders for administering vaccine to persons 18 years of age and older Pfizer-BioNTech COVID-19 vaccine standing orders for administering vaccine to persons 16 years of age and older Prepare to see large volumes of unilateral axillary lymphadenopathy (UAL) on diverse imaging exams in patients recently vaccinated against COVID-19 Document vaccination information (date(s) of vaccination(s), injection site (left/right: arm/thigh), type of vaccine) on all intake forms and ensure this is easily available to the radiologist at the time of exam interpretation In most clinical settings ipsilateral UAL after recent (< 6 weeks) COVID-19 vaccination is a benign imaging finding and clinical follow-up, rather than additional imaging or biopsy In settings with heightened pre-test probability of malignancy, coordinate management plan (additional imaging, short interval imaging follow-up or biopsy) with knowledge of vaccination history and patient risk for metastatic lymphadenopathy Communicate to patients and providers clear guidelines that avoid delays in patient access to both vaccination and recommended imaging for their optimal healthcare throughout the pandemic